The National Agency for Food and Drug Administration and Control has placed products marketed by Mofus Nigeria Limited on its regulatory watchlist following findings of significant regulatory noncompliance and potential misrepresentation.
The agency said the decision was taken as it begins a formal investigation into the products and the companies associated with them. The case is being handled under reference number NAFDAC/PMS/2026/0029, with regulatory authorities maintaining close surveillance while the investigation continues.
The products are associated with Mofus Nigeria Limited, as well as Ayrtons Saunders Limited in the United Kingdom and Pharmaserve North West Limited, another UK based company. The investigation is focused on concerns identified through regulatory activities and post marketing surveillance...READ THE FULL ARTICLE HERE .
As part of its response, NAFDAC said it has activated continuous monitoring of the affected products and notified relevant stakeholders about the development. The agency has also called on healthcare professionals, distributors, medicine vendors and members of the public to remain vigilant when dealing with products marketed by the company.
NAFDAC advised stakeholders to exercise caution when procuring, distributing, dispensing or using the affected products while the investigation is ongoing. It further urged healthcare facilities, pharmacies, distributors and Patent and Proprietary Medicine Vendors to obtain medical products only from licensed and authorised suppliers.
The agency also stressed the importance of maintaining complete distribution records. Such records can help authorities trace products through the supply chain if further regulatory action becomes necessary.
Healthcare professionals and members of the public have equally been encouraged to report suspected quality concerns, irregularities or suspected cases involving substandard or falsified medicines and medical devices to the nearest NAFDAC office.
The watchlist action does not represent the conclusion of the investigation. NAFDAC stated that the products will remain under watch pending the outcome of its regulatory process, meaning further action could depend on what investigators establish.
The development comes amid continued efforts by Nigerian regulators to strengthen surveillance of medicines and other regulated products circulating in the country. NAFDAC operates systems through which registered products can be verified using their registration details, while its regulatory framework allows the agency to monitor products after they enter the market.
For consumers, the agency’s latest advisory reinforces the importance of obtaining medicines and other regulated health products from legitimate and authorised sources. Any suspected irregularity should be reported to the relevant regulatory authorities rather than ignored.
The investigation remains ongoing, and the final regulatory position on the affected products will depend on the findings reached by the agency after completing its assessment.
